Loading
A phase 2 trial of TQB3702 tablets+Chemotherapy regimen in non-Hodgkin lymphoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma is a phase 2 interventional study registered as NCT06566586 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 80 participants planned, started 2024-11-06 and due to reach its primary completion in 2026-03. Interventions recorded: TQB3702 tablets+Chemotherapy regimen.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/